Gilead los­es two more patent chal­lenges on HIV pill, set­ting up court­room fight in Delaware

Gilead sus­tained two more loss­es in their ef­forts to rid them­selves of an ac­tivist-backed patent law­suit from the US gov­ern­ment over a best-sell­ing HIV pill.

Urged on by ac­tivists seek­ing to di­vert a por­tion of Gilead’s rev­enue to clin­ics and pre­ven­tion pro­grams, the De­part­ment of Health and Hu­man Ser­vices made a claim to some of the patents for the best-sell­ing HIV pre­ven­tion drug, Tru­va­da, al­so known as PrEP. Gilead re­spond­ed by ar­gu­ing in court that HHS’s patents were in­valid.

To­day, the US Patent and Trade­mark Of­fice ruled that Gilead was like­ly to lose the last two of those chal­lenges as well. The USP­TO ruled against Gilead on the first two patents ear­li­er this month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER